Treats mild to moderate plaque psoriasis. NDA 22087, held by Galderma Labs LP. Calcitriol.
As of Nov 15, 2026, NDA 22087 (Vectical), held by Galderma Labs LP, was first approved by FDA on Jan 23, 2009, with 1 approved supplement and 0 published complete response letters.
Calcitriol Ointment is a vitamin D analog indicated for the topical treatment of mild to moderate plaque psoriasis in adults and pediatric patients 2 years and older Limitations of Use The safety and effectiveness of Calcitriol Ointment in patients with known or suspected disorders of calcium metabolism have not been evaluated. 1.1 Indication
| Jul 17, 2020 | Supplement 9Efficacy (new indication or use) · Standard review | Approved | |
| Jan 23, 2009 | Original applicationNew dosage form · Standard review | Approved |
| Product | Active ingredient | Marketing |
|---|---|---|
| Vectical3MCG/GM · ointment;topical | Calcitriol | RxReference drug |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters
